Viral replication and microbial translocation from the gut to the blood during HIV infection lead to hyperimmune activation, which contributes to the decline in CD4 + T cell numbers during HIV infection. Programmed death-1 (PD-1) and interleukin-10 (IL-10) are both upregulated during HIV infection. Blocking interactions between PD-1 and programmed death ligand-1 (PD-L1) and between IL-10 and IL-10 receptor (IL-10R) results in viral clearance and improves T cell function in animal models of chronic viral infections. Here we show that high amounts of microbial products and inflammatory cytokines in the plasma of HIV-infected subjects lead to upregulation of PD-1 expression on monocytes that correlates with high plasma concentrations of IL-10. Triggering of PD-1 expressed on monocytes by PD-L1 expressed on various cell types induced IL-10 production and led to reversible CD4 + T cell dysfunction. We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1.
monocytes (CD14 + CD16 − ) and activated (CD14 + CD16 + ) monocytes 27 . We investigated PD-1 expression on monocyte subsets in untreated HIV-infected (viremic), highly active antiretroviral therapy (HAART)-treated HIV-infected (aviremic) ( Supplementary Fig. 1a,b) and healthy subjects. PD-1 expression was higher (~1.5-fold increase) on total, CD16 − and CD16 + monocytes in viremic subjects than in aviremic subjects (P = 0.0003, 0.0001 and 0.01 for each of the monocytes subsets, respectively) and healthy subjects (P = 0.00003, 0.000002 and 0.04; Fig. 1a) . PD-1 expression on CD16 + monocytes were twofold higher (P = 0.00000008, 0.0000005 and 0.0001 for viremic, aviremic and healthy subjects, respectively) than those expressed by CD16 − monocytes (Fig. 1a) . Of note, we did not detect PD-1 on the surface of myeloid dendritic cells (DCs) or plasmacytoid DCs in any donor (data not shown). Moreover, PD-1 expression in all monocyte subsets did not show any correlation with viral load (Fig. 1b) . These results indicate that all monocyte subsets expressed high amounts of PD-1 on their surface during HIV infection through an unknown mechanism. 
Factors that modulate PD-1 expression on monocytes.
We investigated the impact of the bacterial TLR ligands 3 ( Supplementary  Fig. 2 a, (Fig. 2a) , whereas HIV singlestranded RNA (RNA40) 28 , R5 HIV (Ba-L) or X4 HIV (NL4.3) (data not shown) failed to augment PD-1 expression on monocytes (Fig. 2a) . Of note, the circulating inflammatory cytokines such as tumor necrosis factor-α (TNF-α), IL-1β and IL-6, whose expression is elevated during HIV infection [4] [5] [6] [7] [8] [9] ( Supplementary Fig. 2c-e) , also induced a dosedependent increase in PD-1 expression on monocytes (Fig. 2a) . These results prompted the notion that elevated levels of microbial products and inflammatory cytokines in the blood of HIV-infected subjects could be responsible for the upregulation of PD-1 on monocytes. Expression of PD-1 on monocytes was also increased when we incubated peripheral blood mononuclear cells (PBMCs) from healthy subjects with sera from viremic subjects as compared to sera from healthy subjects (n = 16; ~1.3-fold increase, P = 0.0269 and P = 0.0309 for CD16 − and CD16 + monocytes, respectively; Fig. 2b ), thereby suggesting the in vivo relevance of this unconventional expression of PD-1 to HIV pathogenesis. We found high concentrations of IL-10 in the plasma of viremic subjects (approximately threefold increase, P = 0.00008; Supplementary Fig. 2f ) 18, 19 . IL-10 had little or no effect on expression of PD-1 by monocytes (data not shown).
Our results showed that PD-1 expression on total, CD16 − and CD16 + monocytes correlated with IL-10 concentrations in the blood of HIV-infected subjects (P = 0.04, 0.033 and 0.041 and ρ = 0.033, 0.034 and 0.033 for total, CD16 − and CD16 + monocytes, respectively; Fig. 2c ). The direct relation between expression of PD-1 and IL-10 concentrations confirmed the in vivo link between high amounts of PD-1 and IL-10. We did not find any correlation between IL-10 and 16S DNA, LPS, TNF-α, IL6 and IL-1β in the blood of viremic subjects (data not shown).
Ttriggering of PD-1 induces IL-10 production by monocytes.
Stimulation of monocytes with an agonist PD-1-specific induced a tenfold increase in IL-10 production as compared to control goat IgG (n = 7; Fig. 3a ) or antibodies to human leukocyte antigen I (HLA-I) and HLA-II (n = 3; Fig. 3b ), providing further evidence that expression of PD-1 by monocytes and IL-10 production were interrelated. This production was not affected by polymyxin-B, an inhibitor of LPS, (n = 3), which inhibited more than 90% of LPS-induced IL-10 production (Fig. 3c) , indicating that the IL-10 production was not due to contamination with LPS. In addition, monocytes, triggered via PD-1 expressed on their surface, produced IL-10 as early as 6 h after treatment (4.4%) and at 24 h (2.9%) in amounts comparable to those obtained after LPS stimulation (2.4%; Fig. 3d) . We confirmed by ELISA that IL-10 is secreted at 6 h (Fig. 3e) in a dose-dependent manner upon PD-1 triggering (Fig. 3f) , and its secretion reached a maximum at 24 h (a tenfold increase as compared to baseline; Fig. 3e ). In contrast, we did not detect IL-10 production upon PD-1 triggering of CD3 and CD28 preactivated CD8 + or CD4 + T cells (Supplementary Fig. 2h ). Moreover, when we stimulated monocytes from viremic subjects with low concentrations of antibody to PD-1, they produced higher amounts of IL-10 (1.5-fold increase; P = 0.008) than monocytes from healthy donors stimulated with the same antibodies ( Supplementary Fig. 2i ), indicating a correlation between high amounts of PD-1 found on monocytes from HIV-infected donors and IL-10 production by these cells.
Of note, CD16 − monocytes produced twofold higher amounts of IL-10 (8% of cells produced IL-10 at a concentration of 719 pg ml −1 ) than did CD16 + monocytes (5% of cells produced IL-10 at a concentration of 350 pg ml −1 ; P = 0.024 and P = 0.0047, for percentage and concentration, respectively; Fig. 3g ), confirming our results showing higher IL-10 production by CD16 − monocytes 29 . Finally, in vitrodifferentiated macrophages also expressed PD-1 on their surface and produced IL-10 (tenfold increase; P = 0.001) upon PD-1 triggering (Supplementary Fig. 2j ).
Interactions inducing IL-10 production by monocytes
We assessed the impact of PD-1 interaction with its physiological ligands PD-L1 and PD-L2 on IL-10 production by monocytes. We transduced COS-7 cells with lentiviral vectors encoding GFP (COS-mock cells), GFP and human PD-L1 (COS-PD-L1 cells) or GFP and human PD-L2 (COS-PD-L2 cells) (Supplementary Fig. 3a) . Monocytes produced more IL-10 when cocultured with COS-PD-L1 cells than did monocytes cocultured with COS-mock cells ( Fig. 3h; 3 .2% of monocytes cultured with COS-PD-L1 cells; P = 0.0118 and 2.3-fold increase detected by ELISA; P = 0.02). IL-10 production was blocked by the addition of antibody to PD-L1 (P = 0.01). In contrast, monocytes cocultured with COS-PD-L2 did not produce much IL-10 ( Fig. 3h) , although these Cos-PD-L2 cells expressed high levels of PD-L2 (Supplementary Fig. 3a) . LPS, a molecule known to trigger IL-10 production 29 , and PD-1 (at suboptimal levels) acted synergistically to induce twofold increased production of IL-10 by monocytes (Fig. 3i) as compared to the stimulation of monocytes with LPS or antibody to PD-1 alone (P = 0.02 and P = 0.01, respectively). Altogether, these results confirm the role of the PD-1-PD-L1 interaction in inducing IL-10 production.
Monocytes produce IL-10 upon PD-1-PD-L1 interaction
We next investigated the role of the PD-1-PD-L1 interaction in IL-10 production by monocytes during HIV infection. CD16 − and CD16 + monocytes from viremic subjects spontaneously produced IL-10, in contrast to monocytes from healthy subjects 22 (1.5-to twofold increase, P = 0.001 and P = 0.006, respectively; Fig. 4a) . In viremic subjects, IL-10 production was restricted to PD-1 hi monocytes (Fig. 4b) and was inhibited (an average decrease to 45% of the original production; P = 0.00001, P = 0.000008 and P = 0.0002 for total, CD16 − and CD16 + monocytes, respectively) by the addition of antibody to PD-L1 (Fig. 4c) , as also shown by ELISA (Supplementary Fig. 3b ). IL-10 production by monocytes was dependent on PD-L1 on cells interacting with PD-1 + monocytes, as both ELISA (Supplementary Fig. 3c ) and flow cytometry (data not shown) showed a dose-dependent inhibition of IL-10 production by antibody to PD-L1. These results confirmed the key role of the PD-1 -PDL-1 interaction in the induction of IL-10 production by monocytes in HIV -1 disease pathogenesis.
Effect of PD-1 triggering in monocytes on CD4 + T cells
We next investigated the impact of PD-1-dependent IL-10 production by monocytes on CD4 + T cell function, as the stimulation of these latter can be inhibited by IL-10 (ref. 30) . We activated PBMCs labeled with CFSE from healthy, cytomegalovirus-positive (CMV + ) or HIV + subjects with Staphylococcus enterotoxin B (SEB), CMV or HIV peptides, respectively, in the presence or absence of triggering with antibody to PD-1. PD-1 triggering inhibited CD4 + T cell proliferation (40% inhibition (SEB P = 0.00082), 80% inhibition (CMV P = 0.0039) and 67% inhibition (HIV P = 0.0134); Fig. 5a ). This inhibition was reversed by the addition of a blocking antibody to IL-10R (P = 0.0058, P = 0.00042 and P = 0.015 for SEB, CMV and HIV, respectively; Fig. 5a ). + a n t i- + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i-P D -1 + a n t i-I L -1 0 R + a n t i- To confirm that this inhibition was caused by monocyte-produced IL-10, we pretreated monocytes from CMV + or HIV + subjects with antibody specific for PD-1 and then added them to CFSE-labeled PBMCs (depleted of monocytes by positive selection) pulsed with CMV peptides (for CMV + subjects) or HIV peptides (for HIV + subjects; Supplementary Fig. 4a ). PD-1 triggering on monocytes inhibited CD4 + T cell proliferation (an average of a 70% and a 82% decrease in proliferating cells; P = 0.0032 and P = 0.016 for CMV + and HIV + subjects, respectively). Treatment with IL-10R-specific antibody rescued CMV-specific (P = 0.0052) and HIV-specific (P = 0.014) CD4 + T cell proliferation, showing the role of IL-10 in this inhibition (Fig. 5b) . Of note, the magnitude of inhibition of CD4 + T cell proliferation correlated with increased production of IL-10 by monocytes (Supplementary Fig. 4b) . Indeed, CD16 − monocytes, which produce higher amounts of IL-10, showed a 1.6-to 1.8-fold higher inhibition of T cell responses to CMV and HIV peptides when compared to CD16 + monocytes (P = 0.002 and P = 0.035, respectively; Supplementary Fig. 4b ). Antigen-induced CD4 + T cell division was also decreased after monocyte stimulation with antibody to PD-1, as indicated by the higher mean fluorescence intensity (MFI) of CFSE in CFSE lo cells ( Fig. 5a ; 40% to 80% inhibition, P = 0.01, P = 0.005 and P = 0.01 for SEB, CMV and HIV, respectively).
IL-10 production by monocytes on which PD-1 had been triggered also inhibited interferon-γ (IFN-γ) and IL-2 production by CD4 + T cells (Fig. 5c) . Although the frequency of CD4 + T cells secreting IFN-γ (0.9-1.5% and 0.4-1% for cells stimulated with CMV peptides and HIV peptides, respectively) did not change upon addition of monocytes treated with PD-1-specific antibody to peptide-stimulated T cell cultures, the magnitude of IFN-γ expression (MFI) was lower when compared to T cells cocultured with untreated monocytes (average of 40% inhibition; P = 0.0002 and P = 0.0001 for CMV and HIV peptides, respectively). IFN-γ expression was rescued by treatment with IL-10R-specific antibody (P = 0.002 and P = 0.0003 for CMV and HIV for IL-2 production by CMV-specific CD4 + T cells (0.3-0.6%). Indeed, the MFI of IL-2 was lower when we incubated CMV-activated CD4 + T cells with PD-1-triggered monocytes as compared to untreated monocytes (average of 40% inhibition; P = 0.008). IL-2 expression was restored by treatment with IL-10R-specific antibody (P = 0.0001; Fig. 5c and Supplementary Fig. 4c ). We could not detect IL-2 production 31 in HIV-specific CD4 + T cells from viremic subjects.
PD-1 and IL-10 also acted together to inhibit CD4 + T cell proliferation and cytokine production in vitro. Indeed, addition of IL-10 to T cells triggered with PD-1-specific antibodies increased the inhibitory effect of both molecules (70% inhibition of these functions; Fig. 5d and Supplementary Fig. 5a-c ; versus 35% inhibition in the presence of either IL-10 or PD-L1). We observed similar results when we added supernatants from PD-1-triggered monocytes to cell cultures ( Fig. 5d and Supplementary Fig. 5a-c) . Moreover, CD4 + T cell functions were restored by treatment with IL-10R-specific antibody ( Fig. 5d and Supplementary Fig. 5a-c) . Overall, these results showed that PD-1 triggering on monocytes inhibited CD4 + T cell responses by a mechanism that involves IL-10 production and that acts synergistically with the direct effect of PD-1 expressed on T cells.
Signaling in CD4 + T cells induced by IL-10
IL-10 stimulation increases signal transducer and activator of transcription-3 (STAT-3) phosphorylation in CD4 + T cells 32 (2.3-fold increase, P = 0.02; Fig. 6a) . The MFI of p-STAT-3 increased when CD4 + T cells were incubated in the presence of PD-1-stimulated monocytes (1.8-fold, P = 0.038). This upregulation was inhibited by treatment with IL-10R-specific antibody (Fig. 6a) . Notably, we detected significantly higher baseline amounts of p-STAT-3 in CD4 + T cells from HIV-infected subjects as compared to those from healthy subjects (1.29-fold increase, P = 0.004; Supplementary Fig. 5d ).
As expected, CD4 + and CD8 + T cells showed increased PD-1 expression (1.5-fold, P = 0.0007 and P = 0.00001) in viremic subjects as compared to healthy subjects (Supplementary Fig. 6a ). Of note, amounts of IL-10R, PD-1 and PD-L1 on CD4 + T cells from all subjects correlated with one another (ρ = 0.76 and P < 0.0001, Fig. 6b for the correlation with PD-1; ρ = 0.76 and P = 0.012, Fig. 6c for PD-L1 , and r = 0.65 and P = 0.002 for the correlation between PD-1 and PD-L1, Fig. 6d) . HIV-specific CD4 + T cells expressed higher PD-L1 and PD-1 amounts as compared to CMV-specific CD4 + T cells ( Fig. 6e and Supplementary Fig. 6b ; 1.5-fold higher, P = 0.001 and P = 0.004 for PD-L1 and PD-1 expression on CD154 + CD4 + T cells, respectively; P = 0.002 and P = 0.005 for PD-L1 and PD-1 expression on IFN-γ + CD4 + T cells, respectively). As activated CD4 + T cells expressed high amounts of PD-L1 (Fig. 6d) , this might result in a more efficient interaction of these cells with PD-1 + monocytes that would produce increased concentrations of IL-10, leading to the inhibition of T cell functions.
To explore this possibility, we cultured monocytes from HIVinfected subjects with autologous T cells or B cells expressing high amounts of PD-L1 (ref. 33) (Supplementary Fig. 6c-e) . Monocytes produced IL-10 (average of 2% of monocytes produced IL-10; P = 0.0001), and this was inhibited by treatment with PD-L1-specific antibody (P = 0.00008 and P = 0.00005 for T cells and B cells, respectively; Supplementary Fig. 7a,b) . Furthermore, the incubation of CD4 + T cells from viremic donors stimulated for 12 h with CD3-specific and CD28-specific antibodies (to induce the upregulation of PDL-1 (Supplementary Fig. 8a) ) with autologous monocytes triggered higher expression of IL-10 by monocytes when compared to incubation with nonactivated CD4 + T cells from the same subjects (1.8-fold, P = 0.02; Supplementary Fig. 8b ). This was inhibited in a dose-dependent manner by treatment with PD-L1-specific antibody (Supplementary Fig. 8c ). These results show that HIV-specific CD4 + T cells express elevated amounts of PD-L1 and thus are more prone to trigger IL-10 production in PD-1 + monocytes.
DISCUSSION
Here we have shown a direct link between the induction of PD-1 expression by products of microbial translocation or inflammatory cytokines and enhanced production of IL-10 that leads to CD4 + T cell dysfunction in HIV infection. Several results support our conclusions: PD-1 expression is increased on monocytes during HIV infection; PD-1 expression on monocytes is induced by microbial products and inflammatory cytokines present in the blood of viremic subjects; triggering of monocytes by PD-L1 induces IL-10 production and inhibits CD4 + T cell function; this inhibition was blocked by IL-10R-specific antibody; and PD-1 expression on monocytes correlated with the concentration of IL-10 in the blood during HIV infection, whereas IL-10 production by monocytes from HIV-infected subjects was inhibited by blocking the PD-1-PD-L1 interaction.
Binding of PD-1 by PD-L1 triggers IL-10 production during HIV infection. The increased expression of the two components of the PD-1-PD-L1 axis on T cells, B cells and monocytes during HIV infection 33 allows for a better likelihood for the engagement of this pathway, that is, that PD-1 hi monocytes encounter PD-L1 hi cells such as CD4 + T cells. The ensuing production of IL-10 would control T cell activation and avoid hyperimmune activation. However, the prolonged and chronic exposure of immune cells to regulatory factors such as IL-10 and PD-1 during HIV infection results in T cell dysfunction [17] [18] [19] .
PD-1 expression on HIV-specific T cells and its binding by PD-L1 on APCs is a major mechanism that leads to T cell exhaustion during HIV infection [10] [11] [12] [13] . Our results provide a new mechanism by which PD-1-PD-L1 interaction induces immune dysfunction during HIV infection. These two mechanisms could synergize as shown in our in vitro experiments.
Phosphorylated STAT-3 amounts are higher in CD4 + T cells from HIV-infected subjects. This could be due to exposure to elevated IL-10 concentrations, although we cannot exclude the role of other cytokines known to induce STAT-3 phosphorylation, such as IL-6, IL-12 or IL- 21 (refs. 34-36) . Of note, IL-10-dependent STAT-3 phosphorylation is responsible for the induction of macrophage tolerance 32 . Thus, high amounts of p-STAT-3 in CD4 + T cells from HIVinfected subjects could be responsible for their dysfunction [37] [38] [39] .
Notably, Epstein-Barr virus, human papilloma virus, hepatitis B virus and hepatitis C virus (HCV) infections also show high amounts of IL-10 40-44 . We could not observe PD-1 upregulation on monocytes in HCV-infected individuals (n = 11; data not shown), although we cannot exclude that in the liver, the privileged site for HCV replication, monocytes or macrophages can be induced to express high amounts of PD-1. Thus, IL-10 production, resulting from PD-1 triggering on monocytes, could also modulate the immune response in other chronic viral infections.
The expression of PD-1 on APCs and PD-L1 on T cells has been shown to regulate the immune response. Indeed, PD-1 expressed on splenic DCs in Listeria monocytogenes-infected mice negatively regulates DC function 45 . This could be explained by IL-10 production in DCs, although this was never investigated 45 . HIV has been shown to increase the expression of PD-L1 on CCR5 + T cells 46 . Of note, the frequency of cells expressing high amounts of PD-L1 in the natural hosts for simian immunodeficiency virus is low 47 , which may have beneficial effects for the host. This suggests that the absence of PD-1 and PD-L1 on APCs and CD4 + T cells, respectively, improves the immune response by a mechanism that could implicate IL-10. Monocytes or macrophages in humans and mice with sepsis express more PD-1 than do healthy controls 48 . PD-1 upregulation on monocytes or macrophages is associated with the cells' development of cellular dysfunction 48 . In contrast, PD-1-knockout mice are protected from the lethality of sepsis in a monocyte-or macrophage-dependent manner 48 . Moreover, circulating IL-10 concentrations in PD-1 −/− mice are lower than those in wild-type mice during sepsis, and septic PD1 −/− macrophages produce markedly lower amounts of IL-10 than do septic WT macrophages 48 . This corroborates with our results showing that microbial products induce PD-1 upregulation on monocytes during HIV infection and that the triggering of monocyte-expressed PD-1 induces IL-10 production leading to CD4 + T cell dysfunction.
Our results point to the crucial role of blocking both IL-10-IL-10R and PD-1-PD-L1 interactions to restore the immune response during HIV infection 11, 15 . Immunotherapies that interfere with the downregulation of PD-1 and IL-10 should be part of the arsenal used to restore immune function in HIV-infected subjects. Of note, treatment of HCV-infected subjects with IL-10 leads to the suppression of the immune response and to increased viral load 49 . We have also shown that TLR ligands and inflammatory cytokines are major contributors of the nonspecific damage of the immune system through a mechanism that involves PD-1 induction on monocytes and IL-10 production. PD-1 and IL-10 are two immunoregulatory molecules that inhibit T cell function 1,10-13 ; we show here a direct relationship between these two molecules and their impact on immune function. We demonstrate the immunoregulatory consequences of gut microbial product translocation, which provides a further rationale for therapeutic strategies aiming at repairing the gut mucosal damage and preventing microbial translocation and hyperimmune activation in the treatment of HIV-infected subjects.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
